# US 2026/0060966 A1 · Method of preventing or treating heart failure in a patient using (4s)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0060966 A1
- Document ID: US20260060966A1
- Status: Published application
- Kind: A1
- Application number: 19/385,125
- Filed: 2025-11-10
- Published: 2026-03-05
- Earliest claimed: 2024-01-05
- Assignees: Bayer Aktiengesellschaft
- Applicants: Bayer Aktiengesellschaft
- Inventors: Peter KOLKHOF; Patrick SCHLÖMER; Arno FRITSCH; Antonieta BOMFIM WIRTZ; So-Young KIM; Thomas EISSING; John Joseph Valentine MCMURRAY; Scott D. SOLOMON; Bertram PITT; Thomas WENDL; Achim Erhard FRITSCH; Pardeep JHUND
- Web page: https://patentgrep.com/patent/US20260060966A1

## CPC

- A61K 31/4375: the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 9/2095: {Tabletting processes}
- A61K 9/2893: {Tablet coating processes (mechanical aspects A61J3/06)}
- A61K 31/165: having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K 31/277: having a ring, e.g. verapamil
- A61K 31/4164: 1,3-Diazoles
- A61K 31/4166: having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
- A61K 31/427: not condensed and containing further heterocyclic rings
- A61K 31/438: The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
- A61K 31/472: Non-condensed isoquinolines, e.g. papaverine
- A61K 31/496: Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A61K 31/513: having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
- A61K 31/5377: not condensed and containing further heterocyclic rings, e.g. timolol
- A61K 31/55: having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K 31/7048: having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin {, digitoxin or digoxin}
- A61K 31/7056: containing five-membered rings with nitrogen as a ring hetero atom
- A61K 31/706: containing six-membered rings with nitrogen as a ring hetero atom
- A61K 45/06: Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A61K 47/10: Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/04: Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A61P 13/12: of the kidneys
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The disclosure refers to a method of preventing or treating heart failure in a patient using (4S)-4-(4-cyano-2-methoxyphenyl)-5-ethoxy-2,8-dimethyl-1,4-dihydro-1,6-naphthyridine-3-carboxamide (INN: Finerenone).

## Claims

### Claim 1

A method of preventing or treating heart failure in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I)
or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof;
wherein the patient has left ventricular ejection fraction (LVEF) of equal to or above 40%.

### Claim 2 (depends on 1)

The method according to claim 1, wherein the patient has an eGFR of equal to or below 15 mL/min/1.73 m2 and a Urine Albumin to Creatinine Ratio (UACR) of equal to or above 300 mg/g.

### Claim 3 (depends on 1)

The method according to claim 1, wherein at initiation of treatment, the patient has a potassium level of equal to or below 5 mmol/L.

### Claim 4 (depends on 1)

The method according to claim 1, wherein at initiation of treatment, the patient has a potassium level of equal to or above 3.0 to equal to or below 5.0 mmol/L.

### Claim 5

(canceled)

### Claim 6 (depends on 1)

The method according to claim 1, wherein the patient further receives a medication or comedication that is a weak or moderate CYP3A4 inhibitor.

### Claim 7 (depends on 1)

The method according to claim 1, wherein the compound of Formula (I) is administered as a dose of 10, 20 or 40 mg per day.

### Claim 8

(canceled)

### Claim 9

(canceled)

### Claim 10

(canceled)

### Claim 11

(canceled)

### Claim 12 (depends on 6)

The method according to claim 6, wherein the CYP3A4 inhibitor is selected from the group consisting of cyclosporin, ciprofloxacin, clotrimazole, diltiazem, dronedarone, erythromycin, fluconazole, and verapamil.

### Claim 13

(canceled)

### Claim 14 (depends on 1)

The method according to claim 1, wherein the daily dose the patient receives is up-titrated if the potassium level is below 5 mmol/L.

### Claim 15 (depends on 1)

The method according to claim 1, wherein the daily dose is 10 or 20 mg, and the potassium level is below 5 mmol/L, further comprising up-titrating to an up-titrated daily dose of 20 mg or 40 mg.

### Claim 16 (depends on 1)

The method according to claim 1, wherein the daily dose is 40 or 20 mg, and the potassium level is equal to or above 5.5 mmol/L, but below 6.0 mmol/L, further comprising down-titrating to a down-titrated daily dose of 20 mg or 10 mg.

### Claim 17 (depends on 1)

The method according to claim 1, wherein the daily dosing is interrupted, if the potassium level is equal to or above 6.0 mmol/L.

### Claim 18

(canceled)

### Claim 19 (depends on 1)

The method according to claim 1, wherein the patient receives
a moderate or weak CYP3A4 inhibitor and
the compound according to formula (I) in a daily dose selected from the group consisting of 10 mg, 20 mg, 30 mg, and 40 mg,
wherein the daily dose is adjusted by down-titration to a down-titrated daily dose selected from the group consisting of 2.5 mg, 5 mg, 10 mg, 20 mg, and 30 mg.

### Claim 20

(canceled)

### Claim 21 (depends on 19)

The method according to claim 19 wherein the patient receives a target daily dose of the compound of Formula (I) of 40 mg, and the patient's potassium level after initiation becomes greater than or equal to 5.5 to less than 6.0, comprising down-titrating the target daily dose to 20 mg.

### Claim 22

(canceled)

### Claim 23

(canceled)

### Claim 24

(canceled)

### Claim 25

(canceled)

### Claim 26

(canceled)

### Claim 27

A method of preventing or treating heart failure in a patient, comprising administering to the patient a therapeutically effective amount of a compound of Formula (I)
or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof at a dose of 40 mg/day.

### Claim 28 (depends on 19)

The method according to claim 19 wherein the patient receives a target daily dose of the compound of Formula (I) of 20 mg, and the patient's serum potassium level after initiation becomes greater than or equal to 5.5 to less than 6.0, comprising down-titrating the target daily dose to 10 mg when co-administered with a moderate CYP3A4 inhibitor.

### Claim 29

A method for reducing the composite risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in a patient with heart failure, wherein the patient has left ventricular ejection fraction (LVEF) of equal to or above 40%, the method comprising administering to the patient a therapeutically effective amount of a compound of Formula (I)
or a hydrate thereof, solvate thereof, pharmaceutically acceptable salt thereof, or a polymorph thereof.

### Claim 30 (depends on 29)

The method according to claim 29, wherein at initiation of treatment, the patient has a potassium level of equal to or below 5 mmol/L.

### Claim 31 (depends on 29)

The method according to claim 29, wherein at initiation of treatment, the patient has a potassium level of equal to or above 3.0 to equal to or below 5.0 mmol/L.

### Claim 32 (depends on 29)

The method according to claim 29, wherein the patient further receives a medication or comedication that is a weak or moderate CYP3A4 inhibitor.

### Claim 33 (depends on 32)

The method according to claim 32, wherein the CYP3A4 inhibitor is selected from the group consisting of cyclosporin, ciprofloxacin, clotrimazole, diltiazem, dronedarone, erythromycin, fluconazole, and verapamil.

### Claim 34 (depends on 29)

The method according to claim 29, wherein the daily dose the patient receives is up-titrated if the potassium level is below 5 mmol/L.

### Claim 35 (depends on 29)

The method according to claim 29, wherein at initiation of treatment the patient has heart failure with New York Heart Association class II-IV, is ambulatory or hospitalized primarily for heart failure, has an eGFR of greater than or equal to 25 mL/min/1.73 m2 and has serum potassium of less than or equal to 5.0 mmol/L.

### Claim 36 (depends on 29)

The method of claim 29, wherein the patient is administered a daily dosage of 10 mg, 20 mg, or 40 mg.

### Claim 37

A method of reducing the composite risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visits in a patient with heart failure, wherein the patient has left ventricular ejection fraction (LVEF) of equal to or above 40%, comprising administering to the human patient finerenone in amounts that are clinically proven efficacious and safe for heart failure in patients having left ventricular ejection fraction (LVEF) of equal to or above 40%, wherein finerenone is administered in an amount of 10 mg, 20 mg, or 40 mg once daily.

### Claim 38 (depends on 37)

The method according to claim 37, wherein at initiation of treatment, the patient has a potassium level of equal to or below 5 mmol/L.

### Claim 39 (depends on 37)

The method according to claim 37, wherein at initiation of treatment, the patient has a potassium level of equal to or above 3.0 to equal to or below 5.0 mmol/L.

### Claim 40 (depends on 37)

The method according to claim 37, wherein the patient further receives a medication or comedication that is a weak or moderate CYP3A4 inhibitor.

### Claim 41 (depends on 40)

The method according to claim 40, wherein the CYP3A4 inhibitor is selected from the group consisting of cyclosporin, ciprofloxacin, clotrimazole, diltiazem, dronedarone, erythromycin, fluconazole, and verapamil.

### Claim 42 (depends on 37)

The method according to claim 37, wherein the daily dose the patient receives is up-titrated if the potassium level is below 5 mmol/L.

### Claim 43 (depends on 37)

The method of claim 37, wherein at initiation of treatment the patient has heart failure with New York Heart Association class II-IV, is ambulatory or hospitalized primarily for heart failure, has an eGFR of greater than or equal to 25 mL/min/1.73 m2 and has serum potassium of less than or equal to 5.0 mmol/L.
